This collaborative effort enabled Adimmune to upgrade its R & D technology. The CDC issued a press release congratulating Adimmune: "After the failure of the BOO initiative, the ability [of Adimmune] to acknowledge its technical inadequacies and willingness to cooperate with Crucell, which possessed cell culture vaccine manufacturing capacity, is worthy of encouragement. [Adimmune] is indeed a credit to Taiwan's disease control system."
這項合作提升了國光的研發技術，當時疾管局甚至發布新聞稿「恭賀」國光：「（BOO）落榜後，能體認其技術能力之不足，願與擁有細胞培養製造疫苗的 Crucell 公司合作，值得鼓勵，也是台灣防疫體系之幸。」